Press Releases

 
Press Releases
  Date Title View
Apr 7, 2005
SOUTH SAN FRANCISCO, CA/ April 7, 2005 - Theravance, Inc. (NASDAQ: THRX) announced today that results from a series of in vitro studies as well as human clinical studies with the investigational antibiotic telavancin were presented at the 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Copenhagen, April 2-5, 20...
Mar 28, 2005
SOUTH SAN FRANCISCO, CA/ March 28, 2005 - Theravance, Inc. (NASDAQ: THRX) today announced that the U.S. Food and Drug Administration has granted "fast track" designation to telavancin for the treatment of Hospital Acquired Pneumonia (HAP) and complicated skin and skin structure infections (cSSSI).The fast track programs of the Food and ...
Mar 25, 2005
SOUTH SAN FRANCISCO, CA/March 25, 2005 -- Theravance, Inc. (NASDAQ: THRX) announced today that Marty Glick, Theravance's Executive Vice President, Strategy, is scheduled to present at the Lehman Brothers Eighth Annual Global Healthcare Conference on Wednesday, March 30, 2005 at 10:15 a.m. EST (7:15 a.m. PST). The conference will be held from Marc...
Mar 21, 2005
SOUTH SAN FRANCISCO, CA/March 21, 2005 -- Theravance, Inc. (NASDAQ: THRX) announced today that GlaxoSmithKline (GSK) has exercised its option to license Theravance's inhaled bifunctional, muscarinic antagonist/ beta2 agonist (MABA) program under the terms of their 2004 strategic alliance agreement. This program is the third respiratory program ...
Mar 1, 2005
SOUTH SAN FRANCISCO, CA/March 1, 2005 -- Theravance, Inc. (NASDAQ: THRX) announced today that a scientific paper describing the multifunctional mechanism of action of its lead medicine, telavancin, is published in the March 2005 issue of Antimicrobial Agents and Chemotherapy. Telavancin, a rapidly bactericidal injectable antibiotic with a multi...
Feb 17, 2005
SOUTH SAN FRANCISCO, CA/February 17, 2005 -- Theravance, Inc. (Nasdaq: THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to participate in a panel discussion titled "New Antibiotics Against New and Old Threats" at the BIO CEO & Investor Conference to be held Feb. 23-24, 2005 at The Waldorf-Astoria in N...
Feb 16, 2005
Theravance Reports Fourth Quarter And Full Year 2004 Financial ResultsTheravance Reports Fourth Quarter And Full Year 2004 Financial Results Announced Telavancin Phase 2 Study Results Initiated Telavancin Phase 3 Clinical Studies in Hospital Acqui...
Feb 4, 2005
SOUTH SAN FRANCISCO, CA, February 4, 2005 -- Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Tuesday, February 8, 2005 at 1:15 p.m. ET (10:15 a.m. PT). The conference will b...
Feb 3, 2005
SOUTH SAN FRANCISCO, CA/ February 3, 2005-- Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar will join the Company as Senior Vice President and Chief Financial Officer effective March 7, 2005. Aguiar, previously Vice President of Finance at Gilead Sciences, succeeds Marty Glick, whose move to a newly-created position as Execu...
Jan 31, 2005
SOUTH SAN FRANCISCO, CA/ January 31, 2005-- Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the period ended December 31, 2004 after market close on Wednesday, February 16, 2005.An accompanying conference call will be held at 5:00 p.m. Eastern Standard Time. To participate in the live call by t...
FirstPrevious
...
34
NextLast
= add release to Briefcase

Innoviva NASDAQ: INVA

$16.10 0.11 (0.68%) 02/23/18 4:00 PM ET Refresh Quote

Data provided by Nasdaq.
Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.